Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

TB-500 5mg
TB-500 5mg

TB-500 5mg

TB-500 5 mg — Thymosin Beta-4 for research on tissue repair, cell migration and angiogenesis. The mechanism comes from G-actin binding and cytoskeletal dynamics. The freeze-dried form ensures the highest shelf life and freedom to select the working concentration during reconstitution. RUO reagent

24,99 €
With code BLACK: 19,99 € Lowest price in the 30 days before the discount: 24,99 €
Buy more, pay less
Fast shipping
Free delivery from 350 €
Returns policy
View the laboratory analysis report Peptide Calculator

TB-500 5 mg - Thymosin Beta-4 in lyophilized vial, research reagent

  • TB-500 5 mg — Thymosin Beta-4 for research on tissue repair, cell migration and angiogenesis.
  • The mechanism comes from G-actin binding and cytoskeletal dynamics.
  • The freeze-dried form ensures the highest shelf life and freedom to select the working concentration during reconstitution.

Product status information

Chemical reagent intended exclusively for laboratory tests (Research Use Only). It is not a medicinal product, dietary supplement or food. It is not intended for use on humans or animals. Sales only to registered research units and laboratories.

Regulatory Frame – A Critical Nomenclature Distinction

Under the trade name “TB-500”, manufacturers of RUO reagents most often sell synthetic active fragment LKKTETQ (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln) – a short peptide derived from a full-molecule protein Thymosin Beta-4 (Tβ4, 43 amino acids). It’s not always the same molecule. Some of the literature describes the full Tβ4, some only the fragment. The binding signal of batch identity is the sequence and mass confirmed by mass spectrometry at COA. We use the notation “TB-500 (Thymosin Beta-4 or LKKTETQ active fragment – see lot COA for details)” throughout the description and clearly separate full protein data from fragment data.

Introduction

Chronic Achilles tendon injuries or recurrent biceps tears are problems that have frustrated sports medicine for decades – physical therapy and rest help in most cases, but connective tissue repair can be slow and incomplete. Hence the interest of researchers in peptides modulating cell migration and angiogenesis. TB-500 is one of the most frequently mentioned in this context peptides for regeneration from the line Endogenous — comes from the Thymosin Beta-4 protein, naturally present in almost all nucleated cells, involved in the organization of the cytoskeleton and tissue repair.

The Endogenic line in the Pro-Body catalog groups peptides that map to endogenous molecules or their fragments – signals that the body produces on its own and which researchers recreate synthetically as molecular tools. There is some confusion around the name itself, which is worth clearing up at the outset.

“TB-500” is a trade name, not the name of one defined molecule. Full-molecule Thymosin Beta-4 has 43 amino acids and a mass of approximately 4963 g/mol. The active fragment of LKKTETQ – a seven-amino acid stretch responsible for actin binding – weighs approximately 889 g/mol. This fragment is most often traded in RUO under the name “TB-500”, but the distinction depends on the specific batch and its analytical documentation.

In the studies with RegeneRx (phase I/II programs, partially abandoned), the subject was the whole-molecule version of Tβ4 – and this is what most of the literature cited below refers to.

General description

The TB-500 in the Pro-Body catalog is molecular tool intended for research on tissue reparation, cell migration and angiogenesis. We position it in the first pillar of the offer – regenerative peptides – next to BPC-157, with which it is sometimes combined in experimental protocols. The mechanistic difference between these two peptides is fundamental: BPC-157 acts primarily through the VEGF/FAK axis and local cytoprotection, while TB-500 (actually the parent Tβ4) operates at the cytoskeleton level – it binds monomeric G-actin and modulates the dynamics of its polymerization, which determines the ability of cells to migrate. The format of the lyophilized vial is both technical and strategic.

Dry powder is the most stable form of peptide storage – without water, there are no hydrolysis or aggregation reactions in the solution, so the material endures long periods of storage much better than a ready-made solution. The nominal content of 5 mg is an input variant: the researcher reconstitutes the entire vial to a volume adjusted to the planned molarity of the working concentration, with a smaller total pool of material than in the 10 mg vial.

The same mechanism and the same analytical documentation, only a smaller batch – the 5 mg vial works well in piloting the method, in optimizing test conditions and where planned consumption does not justify larger packaging.

Those who need more material for one working batch reach for TB-500 10mg in a larger vial; who prefers a factory solution ready for download – after TB-500 PEN applicator. The same caveat returns in every section and is not a formality: data from the literature describe observations in cellular and animal models and in small clinical programs of full Tβ4. The RUO reagent is not a medicinal form and its role ends on the laboratory bench.

What is TB-500 - full Thymosin Beta-4 and LKKTETQ fragment

This is where the core distinction begins, which determines the correct interpretation of the results. Thymosin Beta-4 (Tβ4) is a naturally occurring, 43-amino acid protein from the beta-thymosin family, one of the most abundant actin-binding proteins in mammalian cells. As an endogenous molecule – produced physiologically in almost all nucleated cells – it defines the affiliation of this reagent to the Endogenic line. Its full sequence is: Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES Within this sequence, an episode LKKTETQ (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln) is the so-called “actin binding motif” – the fragment responsible for the interaction with monomeric G-actin.

It is this seven-amino acid peptide that is most often marked in the RUO trade as “TB-500”. Practical consistency is important. The complete Tβ4 and the isolated LKKTETQ fragment are

two different molecules with different masses, different pharmacokinetic profiles and – in part – different biological activity repertoire. The fragment retains the actin-binding motif, but the full protein carries additional domains involved in angiogenesis, modulation of inflammation, and tissue repair that the heptapeptide alone does not fully reproduce. Therefore, with each observation in the literature, one must ask the question: are we talking about full Tβ4 or a fragment? Registration numbers reflect this duality.

CAS 77591-33-4 refers to full-molecule Tβ4 (43 aa). The fragment LKKTETQ is sometimes assigned CAS 885340-08-9 — we treat this value as indicative and requiring verification in the documentation of a specific batch.

Physicochemical characteristics

Parameter Full Thymosin Beta-4 (Tβ4) Active fragment “TB-500” (LKKTETQ)
Class Actin-binding protein (beta-thymosin family) Synthetic heptapeptide (actin-binding motif)
Number of amino acids 43 7
Sequence Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln
Summary formula C₂₁₂H₃₅₀N₅₆O₇₈S — (depending on the form of salt)
Molecular mass ~4963 g/mol ~889 g/mol
CAS number 77591-33-4 885340-08-9 (verification in the batch COA)
Half-life (Tβ4) ~2–4 h form-dependent fragment data
SC bioavailability 80–100% (Tβ4) depending on form
Physical form — Lyophilisate (sublimated powder) in a vial
Nominal content — 5 mg peptide/vial
HPLC purity ≥98% ≥98%
Identity confirmation Mass spectrometry (MS, Q-TOF) Mass spectrometry (MS, Q-TOF)

Mechanism of action at the molecular level - cytoskeleton as a starting point

Unlike receptor peptides, which trigger a cascade by binding to a specific membrane receptor, Thymosin Beta-4 starts at the cytoskeleton. This is a difference worth emphasizing: the attachment point lies inside the cell, in the apparatus responsible for its shape and movement. The literature describes six to seven complementary axes of activity.

G-actin binding and modulation of cytoskeleton polymerization. This is the core of the mechanism. Tβ4 binds monomeric G-actin (dissociation constant Kd around 0.5 μM), acting as its sequestrant – it regulates the pool of available monomers for the construction of F-actin filaments. In cellular practice, this translates into the cell’s ability to reorganize the cytoskeleton, i.e migration.

Migrating cells are the foundation of every tissue reparation – without the movement of fibroblasts, keratinocytes or endothelial cells, the wound will not close.

Akt/PI3K/mTOR pathway and collagen synthesis. In vitro observations indicate the influence of Tβ4 on Akt/PI3K/mTOR signaling, associated with the synthesis of type I and III collagen in fibroblasts – structural proteins of the extracellular matrix from which tendons and scars are composed.

Angiogenesis (VEGF, FGF-2). Tβ4 has pro-angiogenic activity – models have described the effect on the secretion of vascular endothelial growth factors (VEGF) and fibroblasts (FGF-2). New vessels provide oxygen and substrates to the regenerating tissue.

Keratinocyte migration and reepithelialization. In wound healing models (Sosne et al.), accelerated keratinocyte migration and reepithelialization of the wound surface have been described – an important pathway, among others. for corneal healing research.

Anti-inflammatory effect (NF-κB, macrophage polarization). The literature indicates the modulation of the NF-κB pathway and the effect on switching the macrophage phenotype from pro-inflammatory M1 to reparative M2 – which links the inflammatory phase with the reparative phase.

Hair follicles (anagen phase). In animal models (Philp et al.), the effect of Tβ4 on the activation of hair follicles and the transition to the growth phase (anagen) has been described.

Cardiac repair after ischemia (epicardial cells). Works published in Nature (Bock-Marquette et al.; Smart et al.) described activation of epicardial cells and improved cardiomyocyte survival in murine models of infarction—one of the most frequently cited lines of research on full Tβ4.

Applications in scientific research

TB-500 as an RUO reagent is used in several directions. The lyophilized vial format is particularly useful where the researcher needs to independently define the starting concentration of the mother solution – reconstitution to a selected volume allows you to adjust the molarity to a specific test without the compromises imposed by the ready solution. The smaller 5 mg vial is a convenient format for pilot testing and optimization of conditions before the researcher moves to a larger batch.

Cell migration biology and cytoskeleton dynamics. Migration tests (scratch assay, transwell), imaging of F-actin dynamics, measurements of the effect on G-actin sequestration in cultures of fibroblasts, keratinocytes and endothelial cells.

The lyophilisate allows you to prepare a mother solution with a concentration selected for planned serial dilutions.

Models of connective tissue reparation. Animal models of tendon, muscle and skin damage. Endpoints: wound closure rate, collagen I/III density, scar histology, biomechanical parameters of the repaired tissue. Tβ4 functions as a reference reagent in work on the migration of repair cells. This is a direction close to research on peptides for injuries soft tissues. Angiogenesis. Tube formation assays, matrigel vascularization models, VEGF and FGF-2 expression measurements – Tβ4 as a tool for modulating the pro-angiogenic response.

Experimental cardiology. Mouse models of myocardial ischemia, studies on epicardial cell activation and cardiomyocyte survival – the direction set by work in Nature (Bock-Marquette et al. 2004; Smart et al. 2007).

Experimental dermatology and ophthalmology. Models of cornea and skin healing, studies on reepithelialization and macrophage polarization (Sosne et al.).

Comparative analyzes with BPC-157. Comparison of two different reparation mechanisms – cytoskeletal (Tβ4) and cytoprotective-angiogenic (BPC-157) – in parallel arms of the experiment. The point of reference here is the lyophilised BPC-157 10mg, and in combined protocols – a set BPC-157 + TB-500.

Summary

TB-500 is a reagent with one of the most interesting mechanisms among regenerative peptides – the starting point is not in the membrane receptor, but in the cytoskeleton, at the level of G-actin binding and the dynamics of filament polymerization. It is from this mechanism that the entire cascade results: cell migration, collagen synthesis, angiogenesis, reepithelialization, modulation of inflammation, and in cardiac models – activation of epicardial cells. A rich map of activity, described in the literature dating back to the publication of Nature. Working with this reagent, however, requires conceptual discipline that most peptides do not.

“TB-500” is a trade name for two different molecules: full-molecule Thymosin Beta-4 (43 aa, ~4963 g/mol) and its active fragment LKKTETQ (7 aa, ~889 g/mol). The sequence and mass from the batch COA are the only binding identity signals. The 5 mg variant of the Endogenic line is a smaller vial of the same reagent – the same mechanism, the same analytical documentation, a lower barrier to entry and a format convenient for pilots and smaller batches.

The lyophilized format ensures the highest stability of the peptide in storage (the dry powder does not hydrolyze) and full freedom in selecting the working concentration at the reconstitution stage.

Those who need a larger pool of material reach for the 10 mg variant; who prefers a solution ready for download – the PEN format. All this under the Research Use Only framework, with clear WADA S2 status. The broader comparative context of the two reparation pathways – cytoskeletal TB-500 and angiogenic BPC-157 – is discussed in the review BPC-157 and TB-500 for regeneration.

Bibliography

  1. Goldstein AL, Hannappel E, Sosne G, Kleinman HK (2012). Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. PubMed
  2. Crockford D, Turjman N, Allan C, Angel J (2010). Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. PubMed
  3. Sosne G, Qiu P, Goldstein AL, Wheater M (2010). Biological activities of thymosin beta4 defined by active sites in short peptide sequences. PubMed
  4. Philp D, Nguyen M, Scheremeta B, St-Surin S, Villa AM, et al. (2004). Thymosin beta4 increases hair growth by activation of hair follicle stem cells. PubMed
  5. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. PubMed

Chemical reagent Research Use Only. TB-500 5 mg in the Pro-Body catalog is not a medicinal product, dietary supplement or food. It is not intended for administration to humans or animals outside a controlled experimental environment. It is most often marketed under the name “TB-500”. active fragment of LKKTETQ parent protein Thymosin Beta-4 — the sequence and mass confirmed by mass spectrometry in the COA of the batch determine the identity of the peptide.

TB-500/Tβ4 is on the prohibited list WADA (class S2) as a permanently banned substance since 2011 – registered athletes (ADAMS) must check the current list before making any decision. The information in the description is of an educational and scientific nature and refers to results reported in the literature (mainly cell and animal models, small abandoned clinical programs of full Tβ4) – it does not constitute medical advice or administration instructions.